Physician profile
Victor Macrinici
NPI 1871054056
$2,055.84
in general payments reported to CMS, 2019-2025
19 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $393 · 2023: $432 · 2024: $829 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.55 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $359.20 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $357.34 | 2022-2024 | |
| Edwards Lifesciences Corporation | $210.79 | 2022-2023 | Pascal |
| Bayer Healthcare Pharmaceuticals INC. | $172.64 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.86 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $158.67 | 2023-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $136.79 | 2025 | |
| Novo Nordisk INC | $117.97 | 2024-2025 | Wegovy, Ozempic |
| Amgen INC. | $81.14 | 2022-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $68.23 | 2024-2025 | Xarelto, Uptravi |
| Pfizer INC. | $50.15 | 2024 | |
| Lilly USA, LLC | $37.92 | 2022 | |
| Terumo Medical Corporation | $26.26 | 2022 | |
| Lantheus Medical Imaging, INC. | $25.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $21.66 | 2025 | Farxiga |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $20.12 | 2024 | Onpattro |
| Merck Sharp & Dohme LLC | $16.77 | 2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $15.74 | 2024 | |
| Biosense Webster, INC. | $15.59 | 2023 | Na, Soundstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Macrinici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.